Cercano Management LLC Trims Stake in Eli Lilly and Company $LLY

Cercano Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 14.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 149,387 shares of the company’s stock after selling 24,396 shares during the period. Eli Lilly and Company comprises about 4.4% of Cercano Management LLC’s portfolio, making the stock its 6th largest holding. Cercano Management LLC’s holdings in Eli Lilly and Company were worth $113,982,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Eli Lilly and Company by 0.7% in the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock worth $61,771,785,000 after acquiring an additional 551,659 shares during the last quarter. Laurel Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Norges Bank bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $8,827,714,000. Jennison Associates LLC lifted its holdings in shares of Eli Lilly and Company by 4.3% in the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after purchasing an additional 226,620 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Eli Lilly and Company by 2.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after purchasing an additional 103,119 shares during the period. 82.53% of the stock is currently owned by institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retevmo data: Lilly reported adjuvant/early‑stage lung cancer data showing reduced recurrence risk and improved event‑free survival, broadening the commercial potential of Retevmo and supporting oncology revenue growth. Lilly’s rare cancer drug Retevmo looks to broaden reach with adjuvant trial win
• Positive Sentiment: CSL licensing deal: Lilly secured an exclusive licensing pact around clazakizumab for people with end‑stage kidney disease — a deal that strengthens Lilly’s immunology/kidney disease pipeline and potential near‑to‑midterm revenue streams. CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
• Positive Sentiment: Weight‑loss launch prep: Reports say Lilly has built roughly $1.5B of inventory of its oral GLP candidate Orforglipron ahead of an expected FDA decision, reducing risk of early supply shortfalls and positioning the company to capture market share vs. competitors. Eli Lilly (LLY) Stock: Company Loads Up $1.5B of Weight-Loss Pills to Battle Wegovy
• Positive Sentiment: $1B India investment: Lilly plans roughly $1 billion to expand contract manufacturing and make India a global export hub, which should support supply resilience for high‑demand products (e.g., Mounjaro) and lower long‑term manufacturing costs. Lilly targets India as global export hub amid booming Mounjaro sales, executive says
• Positive Sentiment: AI and R&D expansion: Coverage highlights Lilly’s $1B AI investment and broader push into RNA/oncology and obesity beyond GLP‑1s — a strategic diversification that supports long‑term growth expectations. Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery
• Neutral Sentiment: Marketing/partnership news: Shaquille O’Neal was named ambassador for a Team USA Athlete Recovery Program in partnership with Lilly — useful for brand visibility but unlikely to move fundamentals materially. Basketball legend Shaquille O’Neal named ambassador for Team USA Athlete Recovery Program in partnership with Eli Lilly
• Neutral Sentiment: Investor engagement: Lilly will present at TD Cowen’s healthcare conference (CFO fireside chat), which gives management a forum to reiterate guidance and address investor questions — watch for commentary on margins, inventories and launch timing. Lilly to participate in TD Cowen’s 46th Annual Health Care Conference

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Morgan Stanley raised their target price on Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Wolfe Research increased their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Truist Financial set a $1,281.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Finally, Berenberg Bank boosted their price objective on Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research report on Tuesday, December 2nd. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,218.88.

Eli Lilly and Company Stock Performance

LLY opened at $1,035.82 on Wednesday. The business has a 50 day moving average price of $1,054.36 and a two-hundred day moving average price of $912.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The company has a market capitalization of $977.15 billion, a price-to-earnings ratio of 45.13, a price-to-earnings-growth ratio of 1.21 and a beta of 0.39. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is currently 30.15%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.